Biological and Neuroimaging Markers as Predictors of 5-Year Incident Frailty in Older Adults: A Secondary Analysis of the MAPT Study.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
13 10 2021
Historique:
received: 22 01 2020
pubmed: 28 11 2020
medline: 4 3 2022
entrez: 27 11 2020
Statut: ppublish

Résumé

This study aims to investigate the predictive value of biological and neuroimaging markers to determine incident frailty among older people for a period of 5 years. We included 1394 adults aged 70 years and older from the Multidomain Alzheimer Preventive Trial, who were not frail at baseline (according to Fried's criteria) and who had at least 1 post-baseline measurement of frailty. Participants who progressed to frailty during the 5-year follow-up were categorized as "incident frailty" and those who remained non-frail were categorized as "without frailty." The differences of baseline biochemical factors (25-hydroxyvitamin D, homocysteine, omega-3 index, C-reactive protein), other biological markers (Apolipoprotein E genotypes, amyloid-β deposits), and neuroimaging data (gray matter volume, hippocampal volume, white matter hyperintensities) were compared between groups. Cox proportional hazard model was used to evaluate the associations between biomarkers and incident frailty. A total of 195 participants (14.0%) became frail over 5 years. Although 25-hydroxyvitamin D deficiency, homocysteine levels, low-grade inflammation (persistently increased C-reactive protein 3-10 mg/L), gray matter, and hippocampal volume were significantly associated with incident frailty in unadjusted models, these associations disappeared after adjustment for age, sex, and other confounders. Omega-3 index was the sole marker that presented a trend of association with incident frailty (hazard ratio: 0.92; 95% confidence interval: 0.83-1.01; p = .082). This study failed to identify biomarkers able to predict frailty incidence in community-dwelling older adults for a period of 5 years. Further longitudinal research with multiple measurements of biomarkers and frailty is needed to evaluate the long-term relationships between changes in biomarkers levels and frailty evolution.

Sections du résumé

BACKGROUND
This study aims to investigate the predictive value of biological and neuroimaging markers to determine incident frailty among older people for a period of 5 years.
METHODS
We included 1394 adults aged 70 years and older from the Multidomain Alzheimer Preventive Trial, who were not frail at baseline (according to Fried's criteria) and who had at least 1 post-baseline measurement of frailty. Participants who progressed to frailty during the 5-year follow-up were categorized as "incident frailty" and those who remained non-frail were categorized as "without frailty." The differences of baseline biochemical factors (25-hydroxyvitamin D, homocysteine, omega-3 index, C-reactive protein), other biological markers (Apolipoprotein E genotypes, amyloid-β deposits), and neuroimaging data (gray matter volume, hippocampal volume, white matter hyperintensities) were compared between groups. Cox proportional hazard model was used to evaluate the associations between biomarkers and incident frailty.
RESULTS
A total of 195 participants (14.0%) became frail over 5 years. Although 25-hydroxyvitamin D deficiency, homocysteine levels, low-grade inflammation (persistently increased C-reactive protein 3-10 mg/L), gray matter, and hippocampal volume were significantly associated with incident frailty in unadjusted models, these associations disappeared after adjustment for age, sex, and other confounders. Omega-3 index was the sole marker that presented a trend of association with incident frailty (hazard ratio: 0.92; 95% confidence interval: 0.83-1.01; p = .082).
CONCLUSIONS
This study failed to identify biomarkers able to predict frailty incidence in community-dwelling older adults for a period of 5 years. Further longitudinal research with multiple measurements of biomarkers and frailty is needed to evaluate the long-term relationships between changes in biomarkers levels and frailty evolution.

Identifiants

pubmed: 33246338
pii: 6007777
doi: 10.1093/gerona/glaa296
doi:

Substances chimiques

Biomarkers 0
Fatty Acids, Omega-3 0
Homocysteine 0LVT1QZ0BA
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e361-e369

Investigateurs

Bruno Vellas (B)
Sophie Guyonnet (S)
Isabelle Carrié (I)
Lauréane Brigitte (L)
Catherine Faisant (C)
Françoise Lala (F)
Julien Delrieu (J)
Hélène Villars (H)
Emeline Combrouze (E)
Carole Badufle (C)
Audrey Zueras Methodology (A)
Statistical Analysis (S)
Sandrine Andrieu (S)
Christelle Cantet (C)
Christophe Morin (C)
Gabor Abellan Van Kan (G)
Charlotte Dupuy (C)
Yves Rolland (Y)
Céline Caillaud (C)
Pierre-Jean Ousset (PJ)
Françoise Lala (F)
Sherry Willis (S)
Sylvie Belleville (S)
Brigitte Gilbert (B)
Francine Fontaine (F)
Jean-François Dartigues (JF)
Isabelle Marcet (I)
Fleur Delva (F)
Alexandra Foubert (A)
Sandrine Cerda (S)
Marie-Noëlle-Cuffi Contrib-Type Author (MN)
Corinne Costes (C)
Olivier Rouaud (O)
Patrick Manckoundia (P)
Valérie Quipourt (V)
Sophie Marilier (S)
Evelyne Franon (E)
Lawrence Bories (L)
Marie-Laure Pader (ML)
Marie-France Basset (MF)
Bruno Lapoujade (B)
Valérie Faure (V)
Michael Li Yung Tong (M)
Christine Malick-Loiseau (C)
Evelyne Cazaban-Campistron (E)
Françoise Desclaux (F)
Colette Blatge (C)
Thierry Dantoine (T)
Cécile Laubarie-Mouret (C)
Isabelle Saulnier (I)
Jean-Pierre Clément (JP)
Marie-Agnès Picat (MA)
Laurence Bernard-Bourzeix (L)
Stéphanie Willebois (S)
Iléana Désormais (I)
Noëlle Cardinaud (N)
Marc Bonnefoy (M)
Pierre Livet (P)
Pascale Rebaudet (P)
Claire Gédéon (C)
Catherine Burdet (C)
Flavien Terracol Lyon (F)
Alain Pesce (A)
Stéphanie Roth (S)
Sylvie Chaillou (S)
Sandrine Louchart (S)
Kristel Sudres (K)
Nicolas Lebrun (N)
Nadège Barro-Belaygues (N)
Jacques Touchon (J)
Karim Bennys (K)
Audrey Gabelle (A)
Aurélia Romano (A)
Lynda Touati (L)
Cécilia Marelli (C)
Cécile Pays (C)
Philippe Robert (P)
Franck Le Duff (F)
Claire Gervais (C)
Sébastien Gonfrier (S)
Yannick Gasnier (Y)
Danièle Begorre (D)
Christian Carpuat (C)
Khaled Khales (K)
Jean-François Lefebvre (JF)
Samira Misbah El Idrissi (S)
Pierre Skolil (P)
Jean-Pierre Salles (JP)
Carole Dufouil (C)
Stéphane Lehéricy (S)
Marie Chupin (M)
Jean-François Mangin (JF)
Ali Bouhayia (A)
Michèle Allard (M)
Frédéric Ricolfi (F)
Dominique Dubois (D)
Marie Paule Bonceour Martel (M)
François Cotton (F)
Alain Bonafé (A)
Stéphane Chanalet (S)
Françoise Hugon (F)
Fabrice Bonneville (F)
Christophe Cognard (C)
François Chollet (F)
Pierre Payoux (P)
Thierry Voisin (T)
Julien Delrieu (J)
Sophie Peiffer (S)
Anne Hitzel (A)
Michèle Allard (M)
Michel Zanca (M)
Jacques Monteil (J)
Jacques Darcourt (J)
Laurent Molinier (L)
Hélène Derumeaux (H)
Nadège Costa (N)
Bertrand Perret (B)
Claire Vinel (C)
Sylvie Caspar-Bauguil (S)
Pascale Olivier-Abbal (P)
Sandrine Andrieu (S)
Christelle Cantet (C)
Nicola Coley (N)

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Wan-Hsuan Lu (WH)

Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), France.

Philipe de Souto Barreto (P)

Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), France.
UPS/Inserm UMR1027, University of Toulouse III, France.

Yves Rolland (Y)

Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), France.
UPS/Inserm UMR1027, University of Toulouse III, France.

Ali Bouyahia (A)

CATI Multicenter Neuroimaging Platform, Neurospin, CEA, Gif-sur-Yvette, France.

Clara Fischer (C)

CATI Multicenter Neuroimaging Platform, Neurospin, CEA, Gif-sur-Yvette, France.
Université Paris-Saclay, CEA, CNRS, Neurospin, Baobab, Gif-sur-Yvette, France.

Jean-François Mangin (JF)

CATI Multicenter Neuroimaging Platform, Neurospin, CEA, Gif-sur-Yvette, France.
Université Paris-Saclay, CEA, CNRS, Neurospin, Baobab, Gif-sur-Yvette, France.

Kelly V Giudici (KV)

Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), France.

Bruno Vellas (B)

Gerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital (CHU Toulouse), France.
UPS/Inserm UMR1027, University of Toulouse III, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH